<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Chimeric Therapeutics Limited — News on 6ix</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd</link>
<description>Latest news and press releases for Chimeric Therapeutics Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/chimeric-therapeutics-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836622378dffbe2df15c400.webp</url>
<title>Chimeric Therapeutics Limited</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd</link>
</image>
<item>
<title>Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/minaris-delivers-100percent-manufacturing-and-release-success-for-chimeric-therapeutics-cdh17-autologous-cart-program</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/minaris-delivers-100percent-manufacturing-and-release-success-for-chimeric-therapeutics-cdh17-autologous-cart-program</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics' CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as we</description>
</item>
<item>
<title>Consolidation/Split - CHM</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/consolidationsplit-chm</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/consolidationsplit-chm</guid>
<pubDate>Thu, 19 Mar 2026 01:47:04 GMT</pubDate>
<description>Consolidation/Split - CHM</description>
</item>
<item>
<title>Chimeric receives $1.8 M advance on FY26 R&D tax incentive</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/chimeric-receives-dollar18-m-advance-on-fy26-randd-tax-incentive</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/chimeric-receives-dollar18-m-advance-on-fy26-randd-tax-incentive</guid>
<pubDate>Mon, 02 Mar 2026 04:22:04 GMT</pubDate>
<description>Chimeric receives $1.8 M advance on FY26 R&D tax incentive</description>
</item>
<item>
<title>Half Year Report and Appendix 4D 31 December 2025</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/half-year-report-and-appendix-4d-31-december-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/half-year-report-and-appendix-4d-31-december-2025-2</guid>
<pubDate>Fri, 27 Feb 2026 10:39:15 GMT</pubDate>
<description>Half Year Report and Appendix 4D 31 December 2025</description>
</item>
<item>
<title>Portfolio streamlined - return of CHM CLTX to City of Hope</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/portfolio-streamlined-return-of-chm-cltx-to-city-of-hope</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/portfolio-streamlined-return-of-chm-cltx-to-city-of-hope</guid>
<pubDate>Fri, 27 Feb 2026 03:28:23 GMT</pubDate>
<description>Portfolio streamlined - return of CHM CLTX to City of Hope</description>
</item>
<item>
<title>Funding and EGM update</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/funding-and-egm-update</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/funding-and-egm-update</guid>
<pubDate>Wed, 25 Feb 2026 03:14:28 GMT</pubDate>
<description>Funding and EGM update</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-291</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-291</guid>
<pubDate>Wed, 28 Jan 2026 04:03:17 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>$8.4 M funding to drive CHM CDH17 and resignation of CMO</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/dollar84-m-funding-to-drive-chm-cdh17-and-resignation-of-cmo</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/dollar84-m-funding-to-drive-chm-cdh17-and-resignation-of-cmo</guid>
<pubDate>Tue, 23 Dec 2025 04:14:15 GMT</pubDate>
<description>$8.4 M funding to drive CHM CDH17 and resignation of CMO</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/trading-halt-1407</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/trading-halt-1407</guid>
<pubDate>Fri, 19 Dec 2025 03:51:07 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>CDH17 granted FDA Orphan Drug Designation for Gastric Cancer</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/cdh17-granted-fda-orphan-drug-designation-for-gastric-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/cdh17-granted-fda-orphan-drug-designation-for-gastric-cancer</guid>
<pubDate>Mon, 08 Dec 2025 02:53:16 GMT</pubDate>
<description>CDH17 granted FDA Orphan Drug Designation for Gastric Cancer</description>
</item>
<item>
<title>CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVE</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/chimeric-receives-dollar45m-randd-tax-incentive</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/chimeric-receives-dollar45m-randd-tax-incentive</guid>
<pubDate>Mon, 24 Nov 2025 04:21:05 GMT</pubDate>
<description>CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVE</description>
</item>
<item>
<title>75% disease control observed in CHM CDH17 trial</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/75percent-disease-control-observed-in-chm-cdh17-trial</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/75percent-disease-control-observed-in-chm-cdh17-trial</guid>
<pubDate>Thu, 13 Nov 2025 04:43:04 GMT</pubDate>
<description>75% disease control observed in CHM CDH17 trial</description>
</item>
<item>
<title>CHM CORE NK Combination Phase 1b trial update</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/chm-core-nk-combination-phase-1b-trial-update</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/chm-core-nk-combination-phase-1b-trial-update</guid>
<pubDate>Thu, 13 Nov 2025 04:42:03 GMT</pubDate>
<description>CHM CORE NK Combination Phase 1b trial update</description>
</item>
<item>
<title>Pause in Trading</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/pause-in-trading-1003</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/pause-in-trading-1003</guid>
<pubDate>Thu, 13 Nov 2025 04:30:08 GMT</pubDate>
<description>Pause in Trading</description>
</item>
<item>
<title>Response to ASX Query Letter</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/response-to-asx-query-letter-123</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/response-to-asx-query-letter-123</guid>
<pubDate>Thu, 06 Nov 2025 05:08:12 GMT</pubDate>
<description>Response to ASX Query Letter</description>
</item>
<item>
<title>Additional complete responses in CHM CORE-NK Phase 1b trial</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/additional-complete-responses-in-chm-core-nk-phase-1b-trial</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/additional-complete-responses-in-chm-core-nk-phase-1b-trial</guid>
<pubDate>Thu, 02 Oct 2025 04:03:15 GMT</pubDate>
<description>Additional complete responses in CHM CORE-NK Phase 1b trial</description>
</item>
<item>
<title>Disease control and tumour shrinkage observed in CHM CDH17</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/disease-control-and-tumour-shrinkage-observed-in-chm-cdh17</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/disease-control-and-tumour-shrinkage-observed-in-chm-cdh17</guid>
<pubDate>Mon, 29 Sep 2025 02:50:11 GMT</pubDate>
<description>Disease control and tumour shrinkage observed in CHM CDH17</description>
</item>
<item>
<title>Appendix 4E and Annual Report</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/appendix-4e-and-annual-report-155</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/appendix-4e-and-annual-report-155</guid>
<pubDate>Fri, 29 Aug 2025 11:16:27 GMT</pubDate>
<description>Appendix 4E and Annual Report</description>
</item>
<item>
<title>CHM CDH17 Clinical Trial Update</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/chm-cdh17-clinical-trial-update</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/chm-cdh17-clinical-trial-update</guid>
<pubDate>Mon, 04 Aug 2025 03:18:28 GMT</pubDate>
<description>CHM CDH17 Clinical Trial Update</description>
</item>
<item>
<title>Chimeric receives $2.5 M advance on FY25 R&D tax incentive</title>
<link>https://6ix.com/company/chimeric-therapeutics-ltd/news/chimeric-receives-dollar25-m-advance-on-fy25-randd-tax-incentive</link>
<guid isPermaLink="true">https://6ix.com/company/chimeric-therapeutics-ltd/news/chimeric-receives-dollar25-m-advance-on-fy25-randd-tax-incentive</guid>
<pubDate>Tue, 10 Jun 2025 06:40:10 GMT</pubDate>
<description>Chimeric receives $2.5 M advance on FY25 R&D tax incentive</description>
</item>
</channel>
</rss>